Published in Neurosurgery on January 01, 2012
Functional implications of impaired control of submaximal hip flexion following stroke. Muscle Nerve (2014) 0.86
Understanding tremor in multiple sclerosis: prevalence, pathological anatomy, and pharmacological and surgical approaches to treatment. Tremor Other Hyperkinet Mov (N Y) (2012) 0.80
Targeting thalamic tremor cells in deep brain stimulation for multiple sclerosis-induced complex tremor. Surg Neurol Int (2013) 0.75
[The use of neuromodulation for the treatment of tremor]. Surg Neurol Int (2014) 0.75
Deep brain stimulation for the treatment of uncommon tremor syndromes. Expert Rev Neurother (2016) 0.75
Diagnostic criteria for multiple sclerosis: 2010 revisions to the McDonald criteria. Ann Neurol (2011) 25.66
B-cell depletion with rituximab in relapsing-remitting multiple sclerosis. N Engl J Med (2008) 12.90
Genome-wide association analysis of susceptibility and clinical phenotype in multiple sclerosis. Hum Mol Genet (2008) 3.93
Bilateral deep-brain stimulation of the globus pallidus in primary generalized dystonia. N Engl J Med (2005) 3.88
Subthalamic nucleus stimulation in severe obsessive-compulsive disorder. N Engl J Med (2008) 3.52
Rituximab in patients with primary progressive multiple sclerosis: results of a randomized double-blind placebo-controlled multicenter trial. Ann Neurol (2009) 3.35
Goal-directed and habitual control in the basal ganglia: implications for Parkinson's disease. Nat Rev Neurosci (2010) 3.05
Effect of fetal neural transplants in patients with Huntington's disease 6 years after surgery: a long-term follow-up study. Lancet Neurol (2006) 2.99
Levodopa in the treatment of Parkinson's disease: current controversies. Mov Disord (2004) 2.90
Bilateral, pallidal, deep-brain stimulation in primary generalised dystonia: a prospective 3 year follow-up study. Lancet Neurol (2007) 2.61
Cognitive dysfunction in psychiatric disorders: characteristics, causes and the quest for improved therapy. Nat Rev Drug Discov (2012) 2.44
Vitamin D status is associated with relapse rate in pediatric-onset multiple sclerosis. Ann Neurol (2010) 2.41
Adult polyglucosan body disease: Natural History and Key Magnetic Resonance Imaging Findings. Ann Neurol (2012) 2.33
The adult form of Niemann-Pick disease type C. Brain (2006) 2.33
Long-term results of a multicenter study on subthalamic and pallidal stimulation in Parkinson's disease. Mov Disord (2010) 2.20
Natalizumab treatment for multiple sclerosis: updated recommendations for patient selection and monitoring. Lancet Neurol (2011) 2.19
Rituximab in relapsing-remitting multiple sclerosis: a 72-week, open-label, phase I trial. Ann Neurol (2008) 2.02
Abnormal B-cell cytokine responses a trigger of T-cell-mediated disease in MS? Ann Neurol (2010) 1.97
Neurofascin is a glial receptor for the paranodin/Caspr-contactin axonal complex at the axoglial junction. Curr Biol (2002) 1.94
A three-dimensional, histological and deformable atlas of the human basal ganglia. I. Atlas construction based on immunohistochemical and MRI data. Neuroimage (2006) 1.93
Natural history of multiple sclerosis with childhood onset. N Engl J Med (2007) 1.89
Clinical features and viral serologies in children with multiple sclerosis: a multinational observational study. Lancet Neurol (2007) 1.88
Bilateral pallidal deep brain stimulation for the treatment of patients with dystonia-choreoathetosis cerebral palsy: a prospective pilot study. Lancet Neurol (2009) 1.87
A three-dimensional histological atlas of the human basal ganglia. II. Atlas deformation strategy and evaluation in deep brain stimulation for Parkinson disease. J Neurosurg (2009) 1.74
Riluzole treatment, survival and diagnostic criteria in Parkinson plus disorders: the NNIPPS study. Brain (2008) 1.72
Parkin mutations are frequent in patients with isolated early-onset parkinsonism. Brain (2003) 1.68
Stimulation of subterritories of the subthalamic nucleus reveals its role in the integration of the emotional and motor aspects of behavior. Proc Natl Acad Sci U S A (2007) 1.66
Fingolimod to treat severe multiple sclerosis after natalizumab-associated progressive multifocal leukoencephalopathy: a valid option? Mult Scler (2013) 1.62
Multiple sclerosis therapies in pediatric patients with refractory multiple sclerosis. Arch Neurol (2010) 1.61
Subthalamic nucleus stimulation is efficacious in patients with Parkinsonism and LRRK2 mutations. Mov Disord (2007) 1.58
Dopaminergic function and dopamine transporter binding assessed with positron emission tomography in Parkinson disease. Arch Neurol (2002) 1.54
Behavioral and morphological comparison of two nonhuman primate models of Huntington's disease. Neurosurgery (2002) 1.54
Pathological gambling in Parkinson's disease improves on chronic subthalamic nucleus stimulation. Mov Disord (2006) 1.54
G2019S LRRK2 mutation in French and North African families with Parkinson's disease. Ann Neurol (2005) 1.54
Subthalamic neurostimulation for Parkinson's disease with early fluctuations: balancing the risks and benefits. Lancet Neurol (2013) 1.52
Astrocytes--friends or foes in multiple sclerosis? Glia (2007) 1.52
Pediatric multiple sclerosis. Nat Rev Neurol (2009) 1.50
Spinal cord gray matter atrophy correlates with multiple sclerosis disability. Ann Neurol (2014) 1.50
Imaging of CNS myelin by positron-emission tomography. Proc Natl Acad Sci U S A (2006) 1.49
First episode of acute CNS inflammatory demyelination in childhood: prognostic factors for multiple sclerosis and disability. J Pediatr (2004) 1.48
Restoration of normal motor control in Parkinson's disease during REM sleep. Brain (2007) 1.47
The transmembrane semaphorin Sema4D/CD100, an inhibitor of axonal growth, is expressed on oligodendrocytes and upregulated after CNS lesion. J Neurosci (2003) 1.46
Ciliary neurotrophic factor (CNTF) enhances myelin formation: a novel role for CNTF and CNTF-related molecules. J Neurosci (2002) 1.45
How much phenotypic variation can be attributed to parkin genotype? Ann Neurol (2003) 1.44
Clinical relevance of brain volume measures in multiple sclerosis. CNS Drugs (2014) 1.44
Mutational analysis of the PINK1 gene in early-onset parkinsonism in Europe and North Africa. Brain (2006) 1.41
If I had a clinically isolated syndrome with MRI diagnostic of MS, I would take vitamin D 10,000 IU daily: No. Mult Scler (2013) 1.41
FXTAS: new insights and the need for revised diagnostic criteria. Neurology (2012) 1.39
Exon deletions of SPG4 are a frequent cause of hereditary spastic paraplegia. J Med Genet (2006) 1.37
Localization of stimulating electrodes in patients with Parkinson disease by using a three-dimensional atlas-magnetic resonance imaging coregistration method. J Neurosurg (2003) 1.35
Re-expression of PSA-NCAM by demyelinated axons: an inhibitor of remyelination in multiple sclerosis? Brain (2002) 1.33
Biotin-responsive basal ganglia disease in ethnic Europeans with novel SLC19A3 mutations. Arch Neurol (2010) 1.33
Internal pallidal and thalamic stimulation in patients with Tourette syndrome. Arch Neurol (2008) 1.32
Cognitive impairment in patients with multiple system atrophy and progressive supranuclear palsy. Brain (2010) 1.30
Behavioural disorders induced by external globus pallidus dysfunction in primates: I. Behavioural study. Brain (2004) 1.27
Subthalamic nucleus stimulation reduces abnormal motor cortical overactivity in Parkinson disease. Arch Neurol (2004) 1.27
Aging-related changes in the nigrostriatal dopamine system and the response to MPTP in nonhuman primates: diminished compensatory mechanisms as a prelude to parkinsonism. Neurobiol Dis (2007) 1.26
Retracted Consensus Guidelines for CSF and Blood Biobanking for CNS Biomarker Studies. Mult Scler Int (2011) 1.26
Deep brain stimulation for movement disorders. Front Integr Neurosci (2012) 1.24
Is the subthalamic nucleus hypointense on T2-weighted images? A correlation study using MR imaging and stereotactic atlas data. AJNR Am J Neuroradiol (2004) 1.24
REM sleep behavior disorder and REM sleep without atonia in patients with progressive supranuclear palsy. Sleep (2005) 1.22
Improvement of motor performance and modulation of cortical excitability by repetitive transcranial magnetic stimulation of the motor cortex in Parkinson's disease. Clin Neurophysiol (2004) 1.22
Frequency and phenotypic spectrum of ataxia with oculomotor apraxia 2: a clinical and genetic study in 18 patients. Brain (2004) 1.22
Guillain-Barre syndrome, influenzalike illnesses, and influenza vaccination during seasons with and without circulating A/H1N1 viruses. Am J Epidemiol (2011) 1.21
A novel fluorescent probe that is brain permeable and selectively binds to myelin. J Histochem Cytochem (2006) 1.19
Genetic variants of the alpha-synuclein gene SNCA are associated with multiple system atrophy. PLoS One (2009) 1.19
Gut microbiota in multiple sclerosis: possible influence of immunomodulators. J Investig Med (2015) 1.18
Vitamin D status predicts new brain magnetic resonance imaging activity in multiple sclerosis. Ann Neurol (2012) 1.18
Imaging central nervous system myelin by positron emission tomography in multiple sclerosis using [methyl-¹¹C]-2-(4'-methylaminophenyl)- 6-hydroxybenzothiazole. Ann Neurol (2011) 1.18
Foot, hand, face and eye representation in the human striatum. Cereb Cortex (2003) 1.17
Neuromelanin associated redox-active iron is increased in the substantia nigra of patients with Parkinson's disease. J Neurochem (2003) 1.16
Disease severity and progression in progressive supranuclear palsy and multiple system atrophy: validation of the NNIPPS--Parkinson Plus Scale. PLoS One (2011) 1.15
Compulsions, Parkinson's disease, and stimulation. Lancet (2002) 1.15
Stimulation of the subthalamic nucleus at an earlier disease stage of Parkinson's disease: concept and standards of the EARLYSTIM-study. Parkinsonism Relat Disord (2012) 1.14
Distribution of codon 129 genotype in human growth hormone-treated CJD patients in France and the UK. Lancet (2003) 1.13
Lack of up-regulation of ferritin is associated with sustained iron regulatory protein-1 binding activity in the substantia nigra of patients with Parkinson's disease. J Neurochem (2002) 1.13
Eating disorder and metabolism in narcoleptic patients. Sleep (2007) 1.11
Semaphorin 3A and 3F: key players in myelin repair in multiple sclerosis? Brain (2007) 1.11
Acute flaccid paralysis with anterior myelitis - California, June 2012-June 2014. MMWR Morb Mortal Wkly Rep (2014) 1.10
Association study between iron-related genes polymorphisms and Parkinson's disease. J Neurol (2002) 1.09
Striatal neural grafting improves cortical metabolism in Huntington's disease patients. Brain (2003) 1.09
Alpha-synuclein gene rearrangements in dominantly inherited parkinsonism: frequency, phenotype, and mechanisms. Arch Neurol (2009) 1.07
Long-term effects of pallidal or subthalamic deep brain stimulation on quality of life in Parkinson's disease. Mov Disord (2009) 1.06
Cognitive impairment occurs in children and adolescents with multiple sclerosis: results from a United States network. J Child Neurol (2012) 1.04
Effects of early treatment with glatiramer acetate in patients with clinically isolated syndrome. Mult Scler (2012) 1.04
Coding polymorphisms in the parkin gene and susceptibility to Parkinson disease. Arch Neurol (2003) 1.03
Expectation and the placebo effect in Parkinson's disease patients with subthalamic nucleus deep brain stimulation. Mov Disord (2006) 1.03
Long-term persistence of vaccine-derived aluminum hydroxide is associated with chronic cognitive dysfunction. J Inorg Biochem (2009) 1.03
Switching multiple sclerosis patients with breakthrough disease to second-line therapy. PLoS One (2011) 1.02
Effects of high-frequency stimulation on subthalamic neuronal activity in parkinsonian patients. Arch Neurol (2004) 1.02
Axon-oligodendrocyte interactions during developmental myelination, demyelination and repair. J Neurochem (2010) 1.02
Tourette syndrome deep brain stimulation: a review and updated recommendations. Mov Disord (2014) 1.02
Absence of neuromyelitis optica IgG antibody in an active relapsing-remitting multiple sclerosis population. J Neuroophthalmol (2009) 1.01
Axonal signals in central nervous system myelination, demyelination and remyelination. J Neurol Sci (2005) 1.00
Repetitive behaviours in patients with Gilles de la Tourette syndrome: tics, compulsions, or both? PLoS One (2010) 0.98
Are parkin patients particularly suited for deep-brain stimulation? Mov Disord (2008) 0.97
LRRK2 exon 41 mutations in sporadic Parkinson disease in Europeans. Arch Neurol (2007) 0.97